Version: 1.0.0 | Published: 24 Sep 2026 | Updated: 0 days ago
Documentation
Description:
The Alzheimer’s Prevention Initiative Generation Study, a Generation Program (API Generation) that comprises two separate clinical trials, Generation Study 1 (Gen1) and Generation Study 2 (Gen2). These trials tested experimental Alzheimer’s treatments in individuals who carry one or two copies of the high-risk gene apolipoprotein E ε4 (APOE4). Though the trial was closed before completing enrollment, API Generation generated a large, shareable resource of data including cognitive testing, biomarker analyses, and
and comprehensive trial data.
Generation Study 2 aimed to include more than 2,500 participants that were screened to qualify as cognitively unimpaired (MMSE >=24 and through memory test evaluations) males and females (post-menopausal) aged 60-75 with at least one APOE4 gene. If heterozygous for APOE4, then must have elevated brain amyloid as measured by CSF Abeta or amyloid PET imaging. More than 1,000 of these participants were randomized to the trial.
Cross sectional data are available from those participants that were successfully screened but not randomized to the trial. Longitudinal data are available from those participants who were randomized to the trial protocols (randomized participant data reports varying stages of protocol completion).
Information regarding additional available study resources including PET and MRI neuroimaging and residual biomaterial from Generation Study 2 can be requested through: APIData@bannerhealth.com.
Coverage
Spatial:
US
Follow Up:
Unknown
Provenance
Temporal
Accrual Periodicity:
Static
Start Date:
01 January 2026
Time Lag:
Not applicable
Accessibility
Access
Access Rights:
See dataset for details. Access data at:
Usage
Resource Creators:
Banner Health and Novartis
Observations
Statistical Population
Population Description
Population Size
Measured Property
Observation Date
Persons
1145
Count
01 January 2026